Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies Kohrt, H., Godwin, J. E., Lossos, I. S., Williams, M. E., Timmerman, J., Link, B. K., Goldberg, S. M., McGirr, A., Kurland, J. F., Wigginton, J. M., Cohen, L. J., Levy, R. AMER SOC CLINICAL ONCOLOGY. 2013
View details for Web of Science ID 000335419605402